OncoSil Medical Says 120 German Hospitals Secure Authorization to Negotiate Fee for Cancer Treatment Device; Shares Surge 40%

MT Newswires Live

Feb 04, 2025

OncoSil Medical (ASX:OSL) said the German Institute for the Hospital Remuneration System authorized 120 German hospitals to negotiate fees for the OncoSil device classification under the NUB innovation funding program with statutory health insurance companies as part of annual budget negotiations, according to a Tuesday filing with the Australian bourse.

OncoSil received a "Positive Status 1" classification under the innovation funding program in 2021, the filing said.

In October 2024, the German Federal Joint Committee approved a directive for testing a new treatment method for pancreatic cancer, and in January, approval from the Ministry of Health was received, per the filing.

The Oncosil device is a targetted treatment directly to locally advanced pancreatic cancer delivered via injection and is used in combination with chemotherapy.

Shares surged 40% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2508921103"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508921103\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2508921103?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-04 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508921103","market":"sh","top_or_hot":-1,"title":"OncoSil Medical Says 120 German Hospitals Secure Authorization to Negotiate Fee for Cancer Treatment Device; Shares Surge 40%","media":"MT Newswires Live","content":"<html><body><p> OncoSil Medical (ASX:OSL) said the German Institute for the Hospital Remuneration System authorized 120 German hospitals to negotiate fees for the OncoSil device classification under the NUB innovation funding program with statutory health insurance companies as part of annual budget negotiations, according to a Tuesday filing with the Australian bourse.</p><p>OncoSil received a \"Positive Status 1\" classification under the innovation funding program in 2021, the filing said.</p><p>In October 2024, the German Federal Joint Committee approved a directive for testing a new treatment method for pancreatic cancer, and in January, approval from the Ministry of Health was received, per the filing.</p><p>The Oncosil device is a targetted treatment directly to locally advanced pancreatic cancer delivered via injection and is used in combination with chemotherapy.</p><p>Shares surged 40% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OncoSil Medical Says 120 German Hospitals Secure Authorization to Negotiate Fee for Cancer Treatment Device; Shares Surge 40%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncoSil Medical Says 120 German Hospitals Secure Authorization to Negotiate Fee for Cancer Treatment Device; Shares Surge 40%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-04 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> OncoSil Medical (ASX:OSL) said the German Institute for the Hospital Remuneration System authorized 120 German hospitals to negotiate fees for the OncoSil device classification under the NUB innovation funding program with statutory health insurance companies as part of annual budget negotiations, according to a Tuesday filing with the Australian bourse.</p><p>OncoSil received a \"Positive Status 1\" classification under the innovation funding program in 2021, the filing said.</p><p>In October 2024, the German Federal Joint Committee approved a directive for testing a new treatment method for pancreatic cancer, and in January, approval from the Ministry of Health was received, per the filing.</p><p>The Oncosil device is a targetted treatment directly to locally advanced pancreatic cancer delivered via injection and is used in combination with chemotherapy.</p><p>Shares surged 40% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7048","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2508921103","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508921103","pubTimestamp":1738633147,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OncoSil Medical (ASX:OSL) said the German Institute for the Hospital Remuneration System authorized 120 German hospitals to negotiate fees for the OncoSil device classification under the NUB innovatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7048":"生命科学工具和服务","OSL.AU":"ONCOSIL MEDICAL LTD","BK7508":"医药生物股"},"translate_title":"OncoSil Medical表示，120家德国医院获得了谈判癌症治疗设备费用的授权；股价飙升40%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSL.AU":0.9},"content_text":"OncoSil Medical (ASX:OSL) said the German Institute for the Hospital Remuneration System authorized 120 German hospitals to negotiate fees for the OncoSil device classification under the NUB innovation funding program with statutory health insurance companies as part of annual budget negotiations, according to a Tuesday filing with the Australian bourse.OncoSil received a \"Positive Status 1\" classification under the innovation funding program in 2021, the filing said.In October 2024, the German Federal Joint Committee approved a directive for testing a new treatment method for pancreatic cancer, and in January, approval from the Ministry of Health was received, per the filing.The Oncosil device is a targetted treatment directly to locally advanced pancreatic cancer delivered via injection and is used in combination with chemotherapy.Shares surged 40% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}